# LAGOON (NCT05153239)

> Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05153239
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: PharmaMar
- Conditions: Relapsed Small Cell Lung Cancer
- Interventions: Irinotecan; Lurbinectedin; Irinotecan; Topotecan; Lurbinectedin
- Enrollment: 705
- Primary outcome: Overall survival

## Indexed commentary on LAGOON so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lagoon-nct05153239